G protein-coupled receptors (GPCRs) are promising drug targets due to their pathophysiological role in the body. However, antibody drug development with GPCRs has proven challenging. Twist Bioscience unique DNA writing technology is accelerating GPCR antibody discovery with end-to-end solutions that decrease risk, increase speed, and lower failure rates. Twist “Library of Libraries” offers proprietary antibody phage display libraries to overcome the GPCR drug discovery bottleneck. Learn about the discovery and development of potent antagonist and agonist antibodies that target GLP-1R, a GPCR, and demonstrate in vivo functional activity to treat metabolic diseases. Twist offerings expedite antibody discovery for transformative therapeutics.